Actively Recruiting
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Led by M.D. Anderson Cancer Center · Updated on 2026-03-02
58
Participants Needed
1
Research Sites
446 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.
CONDITIONS
Official Title
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older, or their legally authorized representative, must understand the study and voluntarily sign consent
- Patients under 18 years must have a parent or representative who understands the study and provides consent; assent from minors as appropriate
- Patients aged 1 to under 18 years must weigh at least 8 kg at consent
- Pediatric/adolescent/young adult cohort includes patients aged 1 to under 18 years (weight 68 kg) or 18 to 39 years
- Diagnosis of newly diagnosed or relapsed/refractory AML, MDS, MDS/MPN, myeloid blast phase of MPN including CML, or high-risk malignancies in pediatric/adolescent/young adult group
- Patients on approved or investigational drugs for hematologic malignancies are eligible
- Newly diagnosed patients can enroll within the first 3 cycles of front-line therapy
- Transformed AML from previously treated MDS or MPN allowed
- ECOG performance status of 0 to 3 or Lansky/Karnofsky score 630 at entry
- Laboratory tests within specified limits unless caused by leukemia or malignancy
- Women of childbearing potential must have a negative pregnancy test and use effective contraception; men must agree to contraception
- Measurable extramedullary disease allowed
You will not qualify if you...
- Pregnant or nursing females
- Uncontrolled illnesses such as active infections, symptomatic heart failure, unstable angina, or psychiatric/social issues limiting study compliance
- Diagnosis of acute promyelocytic leukemia (APL)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
M
Maro Ohanian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here